FDA charts path forward for biosimilars — but drug makers aren’t all on board

FDA charts path forward for biosimilars — but drug makers aren’t all on board-stat: In his recent public appearances, Food and Drug Administration Commissioner Scott Gottlieb has sounded a repeating note: drug prices are too high, and especially prices for complicated protein-based drugs called biologics.